Boston Scientific to present multiple long-term data outcomes at the 2026 North American Neuromodulation Society (NANS) Meeting

Three clinical studies reinforce the sustained impact and efficacy of spinal cord stimulation for (SCS) treating chronic pain

MARLBOROUGH, Mass., Jan. 20, 2026 - Boston Scientific Corporation (NYSE: BSX) today announced the company's clinical data that will be featured at the North American Neuromodulation Society (NANS) annual meeting, to be held in Las Vegas, Nevada, on Jan. 22-25, 2026. A total of 17 abstracts, including seven oral presentations, from the chronic pain and deep brain stimulation portfolios have been accepted.

Key findings to be presented include:

• Three-year positive outcomes from a multicenter global real-world study assessing patients using Fast-Acting Sub-perception Therapy (FAST™), designed to provide paresthesia-free pain relief in minutes.
• Three-year results from the global, prospective RELIEF registry highlight long-term outcomes of spinal cord stimulation (SCS) therapy across multiple indications in more than 500 patients.
• Two-year results from the SOLIS (SCS as an Option for Chronic Low Back and/​or Leg Pain Instead of Surgery) randomized controlled trial for non-surgical back pain outcomes for patients using FAST Therapy.

"The data presented at this year's NANS add to the growing body of evidence for our spinal cord stimulation therapies and underscore our category leadership in the pain space," said Jim Cassidy, president, Neuromodulation, Boston Scientific. "By continuing to invest in long-term science and innovation, we're helping physicians offer more personalized, proven treatment options for their patients."

At the meeting, Boston Scientific is also showcasing the Intracept™ EDGE J Stylet, an instrument of the Intracept™ Intraosseous Nerve Ablation System. This latest advancement is designed to optimize access to the basivertebral nerve and streamline the treatment experience. The Intracept procedure is the first U.S. FDA-cleared device-based therapy for vertebrogenic low back pain and has demonstrated improved function and long-term pain relief. Meeting attendees can explore the latest innovation at booth #131, where a hands-on simulator experience will be available.

Featured Abstracts

Oral presentations:

• Long-Term Outcomes of Fast-Acting Sub-Perception SCS: Multinational, Real-World Analysis across Europe and the United States, presented by Jan-Willem Kallewaard, M.D., on Friday, Jan. 23, 2026 from 10:45 a.m.- 10:55 a.m. PT
• Dynamic Stimulation Waveforms in Spinal Cord Stimulation Enhance Benefits of Variable Activation of Dorsal Columns, presented by Tianhe Zhang, Ph.D., on Friday, Jan. 23, 2026 from 11:00 a.m. - 11:10 a.m. PT ​
• Long-Term Spinal Cord Stimulation Outcomes Using Fast-Acting Sub-Perception Therapy Designed to Engage Surround Inhibition, presented by Magdalena Anitescu M.D., Ph.D., on Friday, Jan. 24, 2026 from 4:50 p.m.- 5:09 p.m. PT
• SOLIS RCT: 2-Year Outcomes of SCS vs Medical Management in Surgery-Naïve Back Pain Patients, presented by Drew Trainor, D.O., on Saturday, Jan. 24, 2026 from 11:00 a.m. -11:10 a.m. PT
• Three-Year Outcomes from a Multicenter, European Real-World Study Assessing Patients Using Fast-Acting Sub-Perception Therapy (FAST), presented by Anthony Berg, M.D., on Saturday, Jan. 24, 2026 from 4:30 p.m. - 4:40 p.m. PT
• DYNAMO STUDY: Assessing Dynamic Stimulation Patterns on SCS Efficacy in a Double-blinded Crossover RCT, presented by Ashwin Viswanathan, M.D., on Saturday, Jan. 24, 2026 from 4:40 p.m. - 4:50 p.m. PT
• Three-year Outcomes of Spinal Cord Stimulation Across Multiple Indications: A Prospective, Global, Real-world Registry, presented by Anthony Berg, M.D., on Sunday, Jan. 25, 2026 from 10:59 a.m. - 11:09 a.m. PT​

For a complete list of Boston Scientific clinical and scientific data presentations at NANS 2026, please visit: NANS 2026 - Boston Scientific.

About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn .

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans and product performance and impact, clinical trials, and new and anticipated product approvals and launches. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; geopolitical events; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACTS:
Lisa Ferrer
Media Relations
+1 (805) 561-4075
[email protected]

Lauren Tengler
Investor Relations
+1 (508) 683-4479
[email protected]